Topic:

R&D

Latest Headlines

Latest Headlines

Sage up-sizes its ambition on the eve of a much-watched IPO

Biotech luminary Sage Therapeutics is boosting the size of its planned IPO, upping its share offering and expected price range as investors look to its Wall Street debut as a bellwether for the industry.

Amid positive Q2 sales, St. Jude looks to renal denervation as untapped niche

St. Jude Medical is celebrating positive second-quarter sales fueled by tried-and-true products, but the devicemaker wants to capitalize on an untapped niche in the coming year by focusing on renal denervation.

Plant genes could combat resistance to hemophilia drugs

A biochemist has designed a method for improving the treatment of hemophilia using a plant-based drug delivery system that combats resistance to standard clotting factors, which afflicts about one-fourth of those with the disease. 

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.

Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer

Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.

Delivering breast cancer drug through the skin grants disease prevention

Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.

Immunocore and Lilly strike a risk-sharing deal in oncology R&D

Immunocore has struck another cancer R&D pact with one of the world's top drugmakers, signing a deal with Eli Lilly that'll both bring in short-term revenue and help the biotech build value in its proprietary pipeline.

Merck KGaA brings in a new R&D boss amid its global rethink

Merck KGaA, in the middle of a reformation plot in its biopharma division, has found a new head of drug R&D, moving on after its last research chief lasted just 6 months in the job.

President's advisory group calls for clinical trial changes, incentives for antibiotics R&D

With antibiotic resistance on the rise at a time when Big Pharma has largely left the risk-heavy field, the President's Council of Advisors on Science and Technology is proposing a number of recommendations to lure companies back into the arena and help speed up the development of new antibiotics.

Massachusetts med tech outfit wins $1M from NIH to develop pediatric stent system

480 Biomedical won $1 million in Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to support development of its self-expanding scaffold for patients with pediatric artery stenosis (PAS).